The use of immunotherapies in oncology has drastically changed the way of treating cancer, providing innovative and efficient therapeutic solutions. Currently, tremendous R&D efforts are done in immuno-oncology to discover new targets and develop new drugs. In that context, the use of relevant and robust assays to predict therapeutic efficiencies has become a key for drug discovery programs.
Oncodesign develops a broad range of solutions to support your drug discovery projects in immuno-oncology. We can provide solutions on a stand alone basis or through an integrated drug discovery package - from hit identification to candidate selection.
Based on human immune material for in vitro/ex vivo phenotypic assays and on advanced preclinical models – syngeneic or humanized - for in vivo assays, our scientists help you to assess your compound efficiency in routine or customized assays.
Key learning objectives:
Conference animated by :
Lab Head, Program director,
Business & Marketing,
Marketing & Communication Manager,